Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Purdue Pharma OxyContin

Executive Summary

About 180 sales reps are being retrained "with the presence of [Drug Enforcement Administration] leadership to make sure their...marketing to the medical community makes clear that this drug is only to be used in very isolated incidences," Attorney General of Virginia Mark Earley told a May 14 press briefing. Purdue Pharma's ongoing initiatives to curb diversion and abuse of the drug include temporary suspension of the 160 mg tablet. The National Association of Attorneys General Prescription Drug Abuse Task Force was recently formed to coordinate efforts aimed at preventing OxyContin abuse
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037883

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel